Menu
17/02/2006
Herceptin manufacturer applies for license
The manufacturer of breast cancer drug Herceptin has applied for a license to allow the drug to be used to treat patients in the early stages of the disease.
Herceptin is currently used to treat patients in the advanced stages of breast cancer. However, the drug's manufacturer, Roche, has claimed that the drug halves the risk of the aggressive HER-2 form of the cancer, which affects between 20 - 30% of sufferers, from returning.
Herceptin was licensed for the treatment of patients with advanced breast cancer in March 2002. Roche has now submitted an application to the European Medicines Agency (EMEA) to allow the drug to be used to treat patients in the early stages of the disease.
Guidance from the National Institute for Health and Clinical Excellence will also be fast-tracked. The government has said that the drug will be fast-tracked in England once an early stage license has been received.
A spokesperson for Roche said today: "We are very pleased to have been able to progress this application so rapidly and commend the medical community and regulatory authorities worldwide for their close collaboration and continued support."
The announcement comes after a woman lost her legal bid to be provided the drug, which can cost as much as £21,000 for a year's treatment, on the NHS.
Mother-of-three Ann Marie Rogers lost her High Court battle on Wednesday.
Swindon Primary Care Trust refused to pay for the drug for Ms Rogers, saying that her case was not "exceptional" and that they were acting in accordance with government guidelines.
Ms Rogers, 53, has early stage cancer. During the hearing, she told the court if she did not receive the drug it would be like being given a "death sentence".
NHS funding of Herceptin has been criticised as a "postcode lottery", with some health authorities paying for all eligible applicants, while other fund only exceptional cases.
Last year, Barbara Clarke and Elaine Barber received Herceptin after threatening to take their primary care trusts to court.
(KMcA)
Herceptin is currently used to treat patients in the advanced stages of breast cancer. However, the drug's manufacturer, Roche, has claimed that the drug halves the risk of the aggressive HER-2 form of the cancer, which affects between 20 - 30% of sufferers, from returning.
Herceptin was licensed for the treatment of patients with advanced breast cancer in March 2002. Roche has now submitted an application to the European Medicines Agency (EMEA) to allow the drug to be used to treat patients in the early stages of the disease.
Guidance from the National Institute for Health and Clinical Excellence will also be fast-tracked. The government has said that the drug will be fast-tracked in England once an early stage license has been received.
A spokesperson for Roche said today: "We are very pleased to have been able to progress this application so rapidly and commend the medical community and regulatory authorities worldwide for their close collaboration and continued support."
The announcement comes after a woman lost her legal bid to be provided the drug, which can cost as much as £21,000 for a year's treatment, on the NHS.
Mother-of-three Ann Marie Rogers lost her High Court battle on Wednesday.
Swindon Primary Care Trust refused to pay for the drug for Ms Rogers, saying that her case was not "exceptional" and that they were acting in accordance with government guidelines.
Ms Rogers, 53, has early stage cancer. During the hearing, she told the court if she did not receive the drug it would be like being given a "death sentence".
NHS funding of Herceptin has been criticised as a "postcode lottery", with some health authorities paying for all eligible applicants, while other fund only exceptional cases.
Last year, Barbara Clarke and Elaine Barber received Herceptin after threatening to take their primary care trusts to court.
(KMcA)
Related UK National News Stories
Click here for the latest headlines.
24 May 2006
Herceptin granted UK license
Breast cancer drug Herceptin has been licensed for use in the early stages of the disease in the UK by the European Medicines Agency. The drug, which is already used in Britain to treat the later stages of breast cancer, will now be appraised by the National Institute of Health and Clinical Excellence to see if it is safe and cost-effective.
Herceptin granted UK license
Breast cancer drug Herceptin has been licensed for use in the early stages of the disease in the UK by the European Medicines Agency. The drug, which is already used in Britain to treat the later stages of breast cancer, will now be appraised by the National Institute of Health and Clinical Excellence to see if it is safe and cost-effective.
09 June 2006
Herceptin approved for early breast cancer use on NHS
Breast cancer drug Herceptin has been approved for the treatment of early stage breast cancer on the NHS by the National Institute for Health and Clinical Excellence. Herceptin is effective on the HER2 positive form of breast cancer, which forms around 20% of all breast cancer cases.
Herceptin approved for early breast cancer use on NHS
Breast cancer drug Herceptin has been approved for the treatment of early stage breast cancer on the NHS by the National Institute for Health and Clinical Excellence. Herceptin is effective on the HER2 positive form of breast cancer, which forms around 20% of all breast cancer cases.
25 September 2015
Further Six Arrested In No Deal Operation In Birmingham
A further six people have been arrested as part of an ongoing operation targeting suspected drug dealers in Birmingham. Police carried out a series of dawn raids on Thursday 24 September, arresting a 17-year-old man, two 19-year-olds and three men aged 21, 26 and 47.
Further Six Arrested In No Deal Operation In Birmingham
A further six people have been arrested as part of an ongoing operation targeting suspected drug dealers in Birmingham. Police carried out a series of dawn raids on Thursday 24 September, arresting a 17-year-old man, two 19-year-olds and three men aged 21, 26 and 47.
17 October 2003
54 arrested in swoop on suspected drug dealers
Sellers of the Big Issue were among 54 people arrested by Merseyside Police today in a crackdown on drug dealing in Liverpool city centre. Operation Manton targeted suspected drug dealers and drug users and 50 men and four women were arrested following a 15-month long investigation by Merseyside Police into drug dealing on the city's streets.
54 arrested in swoop on suspected drug dealers
Sellers of the Big Issue were among 54 people arrested by Merseyside Police today in a crackdown on drug dealing in Liverpool city centre. Operation Manton targeted suspected drug dealers and drug users and 50 men and four women were arrested following a 15-month long investigation by Merseyside Police into drug dealing on the city's streets.
17 June 2005
New drug raises hope of cancer treatment
A prototype cancer drug, which could help fight a range of cancers, has shown “promising results” in clinical trials. Scientists from the Institute of Cancer Research found that the 17AAG drug selectively and potently blocked the growth of a wide range of common cancer cells.
New drug raises hope of cancer treatment
A prototype cancer drug, which could help fight a range of cancers, has shown “promising results” in clinical trials. Scientists from the Institute of Cancer Research found that the 17AAG drug selectively and potently blocked the growth of a wide range of common cancer cells.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
